Abstract. Emerging studies have proposed microRNAs (miRNAs) as novel therapeutic tools for cancer therapy. Nucleosome-binding protein 1 (NSBP1) has been suggested as an oncogene in various types of human cancers. The present study aimed to identify a novel miRNA that could directly target and negatively modulate NSBP1 expression. We found that NSBP1 was highly expressed in non-small cell lung cancer (NSCLC) cells, and knockdown of NSBP1 by NSBP1 small interfering RNA (siRNA) significantly suppressed NSCLC cell proliferation and invasion. Bioinformatics analysis revealed that miR-326 had a putative binding site within the 3'-untranslated region of NSBP1. Their substantial relationship was further verified by dual-luciferase reporter assay, real-time quantitative polymerase chain reaction and western blot analysis. Overexpression of miR-326 significantly inhibited NSCLC cell proliferation and invasion, which mimicked the effect of NSBP1 siRNA. Furthermore, suppression of NSBP1 by NSBP1 siRNA or miR-326 overexpression remarkably repressed the expression of cyclin B1 and matrix metalloproteinase 9 (MMP9), which are associated with cancer cell proliferation and invasion. Moreover, overexpression of NSBP1 obviously abolished the inhibitory effect of miR-326 on cyclin B1 and MMP9 expression. In addition, an inverse correlation between miR-326 and NSBP1 expression levels was found in NSCLC clinical specimens. Our study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells. Thus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC.
Introduction
Lung cancer is the leading cause of cancer death among various types of malignant tumours, with the highest morbidity and mortality rates worldwide (1) . According to tumour histologic features, lung cancer can be divided into several subtypes, of which non-small cell lung cancer (NSCLC) occupies >80% of the total lung cancer cases (2) . Although current therapies have achieved certain progress, the disease still shows poor outcomes and low five-year survival rates (<15%) (3, 4) . Therefore, elucidating the pathological mechanism to provide a theoretical basis for developing potential and effective therapies for NSCLC is imperative.
In recent years, microRNAs (miRNAs), a class of 18-22 nucleotide-long small non-coding RNAs, have been recognised as novel regulators for gene expression; miRNAs post-transcriptionally modulate gene expression by targeting the 3'-untranslated region (UTR) of the targets (5, 6) . Thus, miRNAs regulate various cellular processes and participate in the pathogenesis of many diseases (7, 8) . Certain miRNAs are dysregulated in almost all cancer types; these miRNAs do not only contribute to the development and progression of cancers, but also represent novel targets for cancer therapy (9) (10) (11) . Therefore, miRNAs can serve as novel diagnostic biomarkers and potential candidate therapeutic targets.
Nucleosome-binding protein 1 (NSBP1) (also named high-mobility group nucleosome-binding domain 5) has been widely studied because of its ability to modulate gene transcription by binding to chromatin (12) . NSBP1 is broadly distributed in many tissues and is mainly located in the nucleus (13, 14) . NSBP1 is currently recognised as a candidate oncogene in various cancers, including prostate cancer (15) , gliomas (16) , bladder cancer (17) , breast cancer (18) and osteosarcoma (19) . In addition, silencing of NSBP1 suppresses lung cancer cell proliferation (20) . however, the molecular basis of NSBP1 in regulating lung cancer remains unclear. Nevertheless, NSBP1 may be a potential candidate target for developing cancer therapies, including lung cancer. miRNAs are regulators for gene silencing, representing novel therapeutic targets. however, to date, the specific miRNAs that can target and regulate NSBP1 have not been recognised. Thus, the present study aimed to identify a novel miRNA that specifically targets and modulates NSBP1 expression in NSCLC. Bioinformatics analysis revealed that miR-326 had a putative binding site within the 3'-UTR of NSBP1. Their substantial relationship was further verified by dual-luciferase reporter assay, real-time quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. As expected, suppression of NSBP1 by miR-326 overexpression mimicked the effect of NSBP1 silencing by small interfering RNA (siRNA) on NSCLC cell proliferation and invasion. Suppression of NSBP by miR-326 overexpression or NSBP1 siRNA both inhibited the expression levels of cyclin B1 and MMP9, which are associated with tumour cell proliferation and invasion. Further data indicated that miR-326 and NSBP1 expression levels were inversely correlated in NSCLC tissues. Taken together, our study suggested a novel and critical functional significance of miR-326 in NSCLC, and this miRNA was a promising therapeutic candidate for NSCLC by suppressing NSBP1.
Materials and methods
Cell cultures. human NSCLC cell lines NCI-h157 and A549 were obtained from American Type Culture Collection (Manassas, vA, USA). human keratinocyte cell line haCaT and human embryonic kidney cell line hEK293T were purchased from Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). These cells were maintained in DMEM (Invitrogen, Carlsbad, CA, USA) plus 10% fetal calf serum (FCS; Gibco, Rockville, MD, USA) and 1% penicillin/streptomycin (Sigma, St. Louis, MO, USA) and maintained in a humidified incubator containing 95% air/5% CO 2 at 37˚C.
RT-qPCR.
Total RNA was extracted using miRNeasy mini kit (Qiagen, Dusseldorf, Germany) according to the manufacturer's instructions. For mRNA expression analysis, cDNA was reverse transcribed by M-MLv reverse transcriptase (Takara, Dalian, Shanghai). For miRNA expression analysis, cDNA was synthesised with miScript reverse transcription kit (Qiagen). Primer sequences were as follows: NSBP1, forward 5'-GCAGTCAGGCAGTGACTGCCTTCG-3' and reverse 5'-CCCTTTTCTGTGGCATCTTC-3'; GAPDh, forward 5'-CAGTCAG CCG CATCT TCT T T T-3' a nd reverse 5'-GTGACCAGGCGCCCAATAC-3'; miR-326, forward 5'-ACTGTCCTTCCCTCTGGGC-3' and reverse 5'-AATGGT TGTTCTCCACTCTCTCTC-3'; U6 small nuclear RNA, forward 5'-GCTTCGGCAGCACATATACTAAAAT-3' and reverse, 5'-CGCTTCACGAATTTGCGTGTCAT-3'. GAPDh was used as an internal control for mRNA quantification. U6 small nuclear RNA was used as an internal control for miRNA quantification. RT-qPCR analysis was performed using SYBR-Green Master Mix (Bio-Rad, hercules, CA, USA). The relative gene expression was analysed using the 2 -ΔΔCt method and normalised to the internal controls.
Western blot analysis. Cells were lysed in RIPA lysis buffer, and the protein concentration was measured using a BCA kit (Beyotime Biotechnology, haimen, China). Equal amounts of proteins from different samples were separated on 12.5% sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. The separated protein bands on SDS polyacrylamide gel were electro-transferred onto a nitrocellulose membrane (Bio-Rad). After blocking with 5% skim milk powder, the membrane was blotted with NSBP1, cyclin B1, MMP9 and GAPDh antibodies (Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4˚C overnight. Horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.) diluted in 1:2,000 were added and incubated for 1 h at room temperature. Finally, the immunoreactive bands were developed with the enhanced chemiluminescence method. The grey value of protein bands was quantified with Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA), and relative protein expression data were normalised to GAPDh.
Cell transfection. NSBP1-specific siRNA and control non-specific siRNA (NC siRNA) were purchased from Cruz Biotechnology, Inc., and then transfected into cells according to the manufacturer's instructions. In brief, cells were plated into six-well plates at 2x10 5 cells/well overnight. About 1 μg of siRNA was diluted into 100 μl of transfection medium, and 6 μl of transfection reagent was diluted into 100 μl of transfection medium. Both solutions were then mixed together for 45 min at room temperature. The siRNA transfection reagent mixture was added to each well with 0.8 ml of transfection medium and incubated for 7 h. The medium was replaced with fresh normal growth medium and cultured for another 48 h. The interfering efficiency was detected by western blot analysis. miR-326 mimics and non-specific controls (miR-NC) were obtained from Shanghai GenePharma Co., Ltd. (Shanghai, China). NSCLC cells were seeded in six-well plates overnight and then transfected with 50 nM miR-326 mimics or miR-326 inhibitor using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. The transfection efficiency was subsequently detected by RT-qPCR analysis after transfection for 48 h.
Cell proliferation assay. Cell proliferation of NSCLC cells was measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-h-tetrazolium bromide (MTT) method. In brief, NSCLC cells were seeded into 96-well cell plates at a density of 1x10 5 cells/well and grown for 24 h. The cells were then transfected with miR-NC or miR-326 mimics for 48 h. The old medium was replaced by fresh medium containing 20 μl of MTT (5 mg/ml in PBS; Sigma) and cultured for 4 h. The medium was discarded, and 200 μl of dimethyl sulphoxide was added to dissolve crystal formazan. The optical density (OD) of each reaction solution at 490 nm was measured with an enzyme immunoassay analyser (Bio-Tek Instruments, Winooski, vT, USA).
Cell invasion assay. Tumour cell invasion ability was detected by Transwell invasion assay. The Transwell filter was precoated with Matrigel (BD Bioscience, San Jose, CA, USA) on the upper surface of a polycarbonic membrane. NSCLC cells were transfected with miR-326 mimics or miR-NC for 48 h and then starved overnight. A total of 1x10 5 cells were added in the top chamber with serum-free medium, and the medium containing 10% FCS was added to the lower chamber. After 48 h, non-migrated cells in the upper chamber were removed by a cotton swab, and the migrated cells in the lower chamber were fixed with 95% ethanol and stained with 4 g/l trypan blue solution. Cells were observed under a microscope (Olympus, Tokyo, Japan), and positive staining cells were counted in five random fields.
Cell cycle analysis. Cell cycle distribution was detected by flow cytometry. In brief, NSCLC cells were serum-starved for 24 h and transfected with NSBP1 siRNA or miR-326 mimics for 48 h. Thereafter, cells were harvested, washed with ice-cold PBS and fixed with 70% ethanol. Propidium iodide containing RNase (Molecular Probes, Eugene, OR, USA) was added to the cells and incubated for 30 min in the dark. FACScan flow cytometry (Becton Dickinson, Franklin Lakes, NJ, USA) was used to detect the cell cycle distribution.
Dual-luciferase reporter assay. The cDNA fragments from NSBP1 containing an miR-326 binding site were inserted into pmirGLO vector (Promega, Madison, WI, USA). hEK293T cells were seeded into six-well plates at 2x10 5 cells/well overnight. About 10 ng of pmirGLO-NSBP1 recombinant vectors and 50 nM miR-326 mimics were introduced into hEK293T cells using Lipofectamine 2000 (Invitrogen). The transfected cells were lysed after 48 h of transfection. Firefly luciferase activity and Renilla luciferase activity were quantified by the dual-luciferase reporter method (Promega).
NSCLC specimen collection. Twenty pairs of NSCLC tissues and matched adjacent non-tumour tissues were provided by Xi'an Central hospital of Xi'an Jiaotong University. The tissues were collected from NSCLC patients who had undergone surgical resections and stored at -80˚C for use. The use of clinical tissues was approved by the hospital's Institutional human Experiment and Ethic Committee with informed consent from the patients.
Statistical analysis. Data are presented as the mean ± standard deviation (SD). Statistical analyses were carried out using SPSS software (version 11.5; SPSS Inc., Chicago, IL, USA), and statistical differences were analysed using Student's t-test or one-way ANOvA. Correlation analysis was performed using Spearman's rank correlation coefficients. P<0.05 was considered to indicate a statistically significant difference.
Results

NSBP1 is highly expressed in human NSCLC cells.
To explore the potential role of NSBP1 in human NSCLC, the expression patterns of NSBP1 in the NSCLC cell lines were examined by RT-qPCR and western blot analysis. The results showed that the mRNA expression of NSBP1 was significantly higher in A549 and NCI-h157 cells than that in control haCaT cells (Fig. 1A) . Moreover, the NSBP1 protein expression was also highly upregulated in A549 and NCI-h157 cells (Fig. 1B and C) . These results suggested a critical role of NSBP1 in NSCLC cells.
Knockdown of NSBP1 inhibits NSCLC cell proliferation and invasion.
To understand the functional significance of NSBP1 in regulating the biological processes of NSCLC cells, we performed loss-of-function experiments of NSBP1 by transfection with specific siRNA targeting NSBP1. The transfection efficiency was detected by western blot analysis, which showed that NSBP siRNA effectively downregulated the expression of NSBP1 in A549 ( Fig. 2A) and NCI-h157 (Fig. 2B) cells. Subsequently, we measured the effect of NSBP1 suppression on NSCLC cell proliferation. MTT assay showed that knockdown of NSBP1 significantly inhibited A549 (Fig. 2C ) and NCI-h157 (Fig. 2D) cell proliferation. Furthermore, cell cycle distribution showed that knockdown of NSBP1 apparently induced G0/G1 cell cycle arrest of A549 (Fig. 3A) and NCI-h157 (Fig. 3B) cells. To further investigate the biological effect of NSBP1 in NSCLC cells, we examined the effect of NSBP1 knockdown on NSCLC cell invasion. We found that suppression of NSBP1 significantly repressed the invasive ability of A549 (Fig. 3C ) and NCI-h157 (Fig. 3D) cells. In summary, these results indicated that NSBP1 participated in the regulation of NSCLC cell proliferation and invasion. 
miR-326 targets the 3'-UTR of NSBP1 and regulates NSBP1
expression. An increasing number of studies have suggested that miRNAs have the potential to treat lung cancer via targeting specific genes (21) . To date, the miRNAs specifically targeting NSBP1 have not been well characterised. In the present study, we searched for specific miRNAs that could target and regulate NSBP, and investigated whether NSBP1 expression can be regulated by miRNAs. Bioinformatics analysis demonstrated that miR-326 had a predicted binding site in the 3'-UTR of NSBP1 (Fig. 4A) . We then performed a dual-luciferase reporter experiment to verify their direct relationship. The results showed that overexpression of miR-326 markedly repressed the relative luciferase activity of pmirGLO-NSBP1, but it did not affect the relative luciferase activity of pmirGLO-NSBP1 (mut)-transfected cells (Fig. 4B) .
To investigate whether miR-326 can regulate NSBP1 expression in NSCLC cells, we transfected miR-326 mimics into NSCLC cells and detected NSBP1 expression using RT-qPCR and western blot analysis. RT-qPCR analysis showed that miR-326 overexpression significantly suppressed the mRNA expression of NSBP1 in A549 (Fig. 4C) and NCI-h157 (Fig. 4D) cells. Western blot analysis further displayed that the protein expression of NSBP1 was also markedly repressed by miR-326 mimics in A549 (Fig. 4E) and NCI-h157 (Fig. 4F) cells. These results indicated that miR-326 could target the 3'-UTR of NSBP1 and repress its expression in NSCLC cells.
Overexpression of miR-326 suppresses NSCLC cell proliferation and invasion.
Given the inhibitory effect of miR-326 on NSBP1 expression, miR-326 might have a biological effect on NSCLC cells. To test this hypothesis, we examined the biological effect of miR-326 on cell proliferation and invasion in NSCLC cells. Interestingly, MTT assay demonstrated that transfection of miR-326 significantly inhibited cell proliferation of A549 (Fig. 5A ) and NCI-h157 (Fig. 5B) cells. Moreover, miR-326 overexpression induced G0/G1 cell cycle arrest in A549 (Fig. 5C ) and NCI-h157 (Fig. 5D ) cells. The results of Transwell assay suggested that miR-326 mimic-transfected cells showed significantly decreased cell invasive capacity (Fig. 5E and F) .
NSBP1 gene silencing induced by siRNA or miR-326 overexpression represses cyclin B1 and MMP9 in NSCLC cells.
To further understand the molecular basis of NSBP1 gene silencing induced by NSBP1 siRNA or miR-326 in regulating NSCLC cell proliferation and invasion, we detected the regulatory effect of NSBP1 gene silencing on cyclin B1 and MMP9, which were involved in regulating cancer cell proliferation and invasion. We found that suppression of NSBP1 by siRNA or miR-326 inhibited the protein expression levels of cyclin B1 and MMP9 in A549 (Fig. 6A and B) .
miR-326 regulates cyclin B1 and MMP9 expression through NSBP1.
To investigate whether miR-326 overexpression suppressed cyclin B1 and MMP9 directly through NSBP1, we performed a rescue experiment by overexpression of NSBP1. We found that transfection of NSBP expression vectors harbouring no 3'-UTR of NSBP1 significantly restored NSBP1 expression, which was decreased by the transfection of miR-326 mimics ( Fig. 7A and B) . NSBP1 overexpression restored the decreased protein expression levels of cyclin B1 and MMP9 induced by miR-326 overexpression (Fig. 7A, C and D) , indicating that miR-326 inhibited cyclin B1 and MMP9 expression through NSBP1.
miR-326 expression is inversely correlated with NSBP1 expression in NSCLC specimens. To gain insight into the functional significance of miR-326 and NSBP1 expression in NSCLC, we uncovered their expression levels in clinical NSCLC tissues and elucidated their potential relationship. We found that NSBP1 mRNA expression was significantly increased in NSCCL specimens (Fig. 7E) , whereas miR-326 expression was markedly decreased (Fig. 7F ) compared with that in adjacent non-tumour tissues. We correlated NSBP1 mRNA expression and miR-326 expression using correlation analysis, which demonstrated that miR-326 expression was remarkably inversely correlated with NSBP1 expression in NSCLC tissues (Fig. 7G) (r=-0.8756, P<0.001), implying that decreased miR-326 might contribute to the increased NSBP1 expression during NSCCL development and progression.
Discussion
The present study showed that suppression of NSBP1 by miR-326 could inhibit NSCLC cell proliferation and invasion. We demonstrated that NSBP1, which functioned as an oncogene in NSCLC, could be targeted by miR-326. Overexpression of miR-326 significantly inhibited NSBP1 expression, which was analogous to NSBP1 siRNA. Our study suggested that miR-326 was a novel therapeutic target for treating NSCCL by suppressing NSBP1.
NSBP1 plays a critical role in modulating gene transcription (12) . Thus, dysregulation of NSBP1 may be associated with disease generation and development. Increasing evidence revealed that NSBP1 is extensively involved in tumourigenesis. Jiang et al reported that knockdown of NSBP1 by RNA interference inhibits prostate cancer cell proliferation in vitro and in vivo (15) . Knockdown of NSBP1 causes cell cycle arrest and promotes cell apoptosis of prostate cancer cells possibly by inhibiting cyclin B1 and Bcl-2 expression levels (15) . Similarly, Zhang et al showed that NSBP1 gene silencing results in increased mitochondria-mediated cell apoptosis in prostate cancer cells (22) . Furthermore, NSBP1 is overexpressed in glioma clinical tissues, and knockdown of NSBP1 induces cell cycle arrest in the G1 phase, inhibits cell proliferation and promotes cell apoptosis in glioma cells in vitro (16) . Moreover, NSBP1 was demonstrated to be overexpressed in bladder cancer (17) , clear cell renal cell carcinoma (23) , osteosarcoma (19) and breast cancer (18) . These studies also reported that NSBP1 regulated cancer cell proliferation, apoptosis and invasion. In the present study, we found that NSBP1 was highly expressed in NSCLC cells, and knockdown of NSBP1 by NSBP1 siRNA significantly inhibited cell proliferation and invasion of NSCLC cells. Furthermore, knockdown of NSBP1 suppressed cyclin B1 and MMP9 expression levels, which might be the molecular basis for NSBP1 knockdown-induced decreased cell proliferation and invasion of NSCLC cells. Our results were consistent with the findings of Chen et al, who reported that knockdown of NSBP1 by siRNA inhibits cell proliferation and induces cell cycle arrest in the G1 phase in lung cancer cells (20) . Notably, high expression of NSBP1 was also found to be associated with drug resistance and ionising radiation in cancer cells (24, 25) . Collectively, our data, as well as the aforementioned findings, support the notion that NSBP1 could be a candidate target for developing cancer therapies.
Recent emerging studies have proposed miRNAs as novel therapeutic tools for cancer treatment by negatively modulating target gene expression (5,6,9-11). These reports prompted us to identify specific miRNAs that could target and regulate NSBP1 expression. Intriguingly, we found that miR-326 possessed a predicted binding site in the 3'-UTR of NSBP1, implying that miR-326 may directly modulate NSBP1 expression. Dual-luciferase activity validated the interaction between miR-326 and NSBP1 3'-UTR. Further experiments using RT-qPCR and western blot analysis confirmed that miR-326 inhibited NSBP1 expression in NSCLC cells. Strikingly, overexpression of miR-326 markedly inhibited cell proliferation and invasion of NSCLC cells, which mimicked the effect of NSBP1 siRNA, suggesting that miR-326 exerted a tumour suppressive function by inhibiting NSBP1 expression. Several studies have reported the potential therapeutic function of miR-326 against tumours. Kefas et al revealed that transfection of miR-326 significantly decreases cell growth and cell tumourigenicity of glioma cells (26, 27) . Similarly, miR-326 expression is low in glioma tissues, and low miR-326 expression is associated with advanced pathological grade of gliomas (28) . In pancreatic ductal adenocarcinoma, miR-326 significantly decreased in patients, and patients with relatively high miR-326 expression displayed long-term survival or without venous invasion, implying that miR-326 is a tumour suppressor in pancreatic ductal adenocarcinoma (29) . Moreover, miR-326 was shown to exert a tumour suppressive role in glioma (30) or colorectal cancer (31) by targeting the Nin one binding protein that can inhibit cancer cell proliferation, migration and invasion, and promote cell apoptosis. Interestingly, miR-326 was found to suppress cancer cell invasion by targeting the disintegrin and metalloprotease 17 in lung adenocarcinoma (32) . In line with these findings, we also found that miR-326 was frequently downregulated in NSCLC tissues, and overexpression of miR-326 inhibited cancer cell proliferation and invasion. These findings suggested that miR-326 functioned as a tumour suppressor.
Taken together, our study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells. Loss of NSBP1 induced by NSBP1 siRNA or miR-326 overexpression repressed the expression levels of cyclin B1 and MMP9, which contribute to cancer cell proliferation and invasion. Conversely, overexpression of NSBP1 apparently rescued the decreased cyclin B1 and MMP9 expression levels induced by miR-326 overexpression, further confirming that miR-326 exerted its tumour suppressive function by targeting NSBP1. Most importantly, we observed that miR-326 expression was inversely correlated with NSBP1 expression in NSCLC clinical specimens, further confirming its functional significance in NSCLC. Therefore, our study suggested that miR-326-NSBP1 could be employed as a promising candidate target for developing novel anticancer therapeutics for NSCLC.
